Quick Answer
NEKTAR THERAPEUTICS reported Operating Income of -$140.10 million for fiscal year 2025.
NEKTAR THERAPEUTICS Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$140.10M | -33.2% |
| 2024 | -$105.20M | +60.1% |
| 2023 | -$263.68M | +29.9% |
| 2022 | -$376.17M | +15.7% |
| 2021 | -$446.10M | -4.9% |
| 2020 | -$425.11M | +3.4% |
| 2019 | -$440.04M | -164.0% |
| 2018 | $687.93M | +1253.4% |
| 2017 | -$59.64M | +47.2% |
| 2016 | -$112.86M | -284.2% |
| 2015 | -$29.37M | -78.2% |
| 2014 | -$16.48M | +86.3% |
| 2013 | -$120.13M | +14.9% |
| 2012 | -$141.20M | -13.9% |
| 2011 | -$123.94M | -338.6% |
| 2010 | -$28.25M | +70.3% |
| 2009 | -$95.13M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$31.67M | +7.8% | +12.6% |
| June 30, 2025 | -$36.23M | +27.2% | +18.6% |
| March 31, 2025 | -$44.53M | -25.7% | -29.7% |
| September 30, 2024 | -$34.34M | +23.4% | +31.0% |
| June 30, 2024 | -$49.77M | +1.6% | -40.5% |
| March 31, 2024 | -$35.43M | +73.7% | +21.0% |
| September 30, 2023 | -$44.86M | +17.4% | +11.3% |
| June 30, 2023 | -$50.60M | +66.9% | +62.4% |
- NEKTAR THERAPEUTICS showed a decrease of -33.2% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, NEKTAR THERAPEUTICS’s operating income has declined by 47.3% (from -$95.13 million to -$140.10 million).
- The most recent figure is from NEKTAR THERAPEUTICS’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: